These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 32888499)
21. IRAK4 inhibition to shut down TLR signaling in autoimmunity and MyD88-dependent lymphomas. Küppers R J Exp Med; 2015 Dec; 212(13):2184. PubMed ID: 26666751 [No Abstract] [Full Text] [Related]
22. IRAK4 kinase activity is redundant for interleukin-1 (IL-1) receptor-associated kinase phosphorylation and IL-1 responsiveness. Qin J; Jiang Z; Qian Y; Casanova JL; Li X J Biol Chem; 2004 Jun; 279(25):26748-53. PubMed ID: 15084582 [TBL] [Abstract][Full Text] [Related]
23. Targeting IRAK4 for Degradation with PROTACs. Nunes J; McGonagle GA; Eden J; Kiritharan G; Touzet M; Lewell X; Emery J; Eidam H; Harling JD; Anderson NA ACS Med Chem Lett; 2019 Jul; 10(7):1081-1085. PubMed ID: 31312412 [TBL] [Abstract][Full Text] [Related]
24. Small Molecule Inhibition of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4). Genung NE; Guckian KM Prog Med Chem; 2017; 56():117-163. PubMed ID: 28314411 [TBL] [Abstract][Full Text] [Related]
25. Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders. Chaudhary D; Robinson S; Romero DL J Med Chem; 2015 Jan; 58(1):96-110. PubMed ID: 25479567 [TBL] [Abstract][Full Text] [Related]
26. A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF- Yoon SB; Hong H; Lim HJ; Choi JH; Choi YP; Seo SW; Lee HW; Chae CH; Park WK; Kim HY; Jeong D; De TQ; Myung CS; Cho H Acta Pharm Sin B; 2023 Mar; 13(3):1093-1109. PubMed ID: 36970199 [TBL] [Abstract][Full Text] [Related]
27. Anticancer activity of IRAK-4 inhibitors against canine lymphoid malignancies. Park JH; Lee JH; An JH; Park CW; Choi YP; Seo SW; Lee HW; Youn HY Vet Comp Oncol; 2022 Sep; 20(3):632-640. PubMed ID: 35340094 [TBL] [Abstract][Full Text] [Related]
28. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825. Wang X; Tan Y; Huang Z; Huang N; Gao M; Zhou F; Hu J; Feng W Oncol Rep; 2019 Nov; 42(5):1755-1766. PubMed ID: 31432184 [TBL] [Abstract][Full Text] [Related]
29. IRAK4 in TLR/IL-1R signaling: possible clinical applications. Li X Eur J Immunol; 2008 Mar; 38(3):614-8. PubMed ID: 18286571 [TBL] [Abstract][Full Text] [Related]
30. Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs. Chen Y; Ning Y; Bai G; Tong L; Zhang T; Zhou J; Zhang H; Xie H; Ding J; Duan W ACS Med Chem Lett; 2021 Jan; 12(1):82-87. PubMed ID: 33488968 [TBL] [Abstract][Full Text] [Related]
31. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation. Yao S; Xu F; Chen Y; Ge Y; Zhang F; Huang H; Li L; Lin D; Luo X; Xu J; Luo D; Zhu X; Liu Y J Exp Clin Cancer Res; 2017 Jan; 36(1):10. PubMed ID: 28069035 [TBL] [Abstract][Full Text] [Related]
32. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955 [TBL] [Abstract][Full Text] [Related]
33. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Naylor TL; Tang H; Ratsch BA; Enns A; Loo A; Chen L; Lenz P; Waters NJ; Schuler W; Dörken B; Yao YM; Warmuth M; Lenz G; Stegmeier F Cancer Res; 2011 Apr; 71(7):2643-53. PubMed ID: 21324920 [TBL] [Abstract][Full Text] [Related]
34. Discovery and optimization of a potent and selective indazolamine series of IRAK4 inhibitors. Zhai W; Lu Y; Zhu Y; Zhou M; Ye C; Shi ZZ; Qian W; Hu T; Chen L Bioorg Med Chem Lett; 2021 Jan; 31():127686. PubMed ID: 33242574 [TBL] [Abstract][Full Text] [Related]
35. Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4. McElroy WT; Michael Seganish W; Jason Herr R; Harding J; Yang J; Yet L; Komanduri V; Prakash KC; Lavey B; Tulshian D; Greenlee WJ; Sondey C; Fischmann TO; Niu X Bioorg Med Chem Lett; 2015 May; 25(9):1836-41. PubMed ID: 25870132 [TBL] [Abstract][Full Text] [Related]